^
    Back
    Association details:
    Biomarker:RNPC3‐JAK2 fusion + Chr t(1;9)(p13;p22)
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    New
    Source:
    Mol Genet Genomic Med
    Title:

    Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib

    Excerpt:
    Here, we report the identification of a novel RNPC3‐JAK2 fusion in a refractory case of B‐ALL with rare t(1;9)(p13;p22) translocation….She was treated with a combination of chemotherapy and targeted drug ruxolitinib and chimeric antigen receptor T‐cell therapy, but failed to achieve complete remission.
    Secondary therapy:
    CAR-T cell immunotherapy + Chemotherapy
    DOI:
    10.1002/mgg3.1110